An observational study in HIV Infection and Sexual and Reproductive Health, sponsored by Desmond Tutu HIV Foundation. Recruiting at 1 site in South Africa. Open to participants aged 15 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Desmond Tutu HIV Foundation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 305 studies in HIV Infections with a site in South Africa — 15 open to participants now, 36 under way, 15 of them phase 3. HIV Infections · South Africa.
Among the 305 studies in HIV Infections with a site in South Africa, this one is the 3rd largest by planned enrollment of the 35 observational ones that give a count, is one of 11 that started in 2024, is one of 35 observational ones, reaches primary completion later than 16 of the 35 other live ones, and was the 300th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →15 of the 305 studies in HIV Infections with a site in South Africa are open now. Recruiting first, the newest first:
ViiV Healthcare · Sites in South Africa, Romania, Uganda
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
Emory University · Sites in South Africa
Ages 18+ · Men only · Healthy volunteers
University of Illinois at Chicago · Sites in South Africa
Ages 18+ · Healthy volunteers
University of California, San Francisco · Sites in South Africa
A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 15 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
305 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 60 · Phase 2 92 · Phase 3 85 · Phase 4 21
First in 1999; this study’s year is marked. 11 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,800 is above the median of 200 across 781 observational studies indexed under HIV Infections.
Median enrollment 280 across the 267 interventional studies, 513 across the 35 observational. Of the 248 that completed or were terminated, 128 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
77 of 305 have an industry lead sponsor. The 10 most frequent:
Desmond Tutu HIV Foundation is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Desmond Tutu HIV Foundation has 3 studies filed under HIV Infections — fewer than ten, so there is no comparison to draw.
9 of the studies in HIV Infections with a site in South Africa that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06694753International AIDS Vaccine InitiativeSafety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in South Africa. | 2026-12-08 |
| NCT05602376Desmond Tutu HIV FoundationImproving HIV Testing, Linkage, and Retention in Care for Men Through U=U Messaging | 2026-12-31 |
| NCT05553236University of California, San FranciscoPragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis | 2027-01 |
| NCT05933226University of Maryland, College ParkProject Khanya: Peer-Delivered Intervention to Improve HIV Medication Adherence and Substance Use in South Africa | 2027-02 |
| NCT05633056Columbia UniversityAn Adaptive Randomized Controlled Trial | 2027-04 |
Add all 9 to your calendar (.ics) → With an account.
Among the 305 studies in HIV Infections with a site in South Africa, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to offer adolescents and young people in Cape Town, South Africa different HIV pre-exposure prophylaxis (PrEP) products and describe how they use these products over an 18-month period. The study has both clinical and implementation primary aims. The primary clinical aim is short and long-term persistence on PrEP. Persistence is defined as the length of time that a participant shows continuous use of a PrEP product as intended, without stopping PrEP or switching to another PrEP product. The primary implementation aim involves the determination of factors that either enable or serve as a barrier to PrEP uptake and continuation.
Participants will be offered a choice between three antiretroviral-containing PrEP products: (1) a Tenofovir-based oral tablet that needs to be taken daily; (2) a vaginal ring containing Dapivirine that provides HIV protection for up to one month; and (3) an intramuscular injection containing Cabotegravir that provides HIV protection for up to two months. Participants will be able to use the same product throughout the study, switch between products, or stop and restart on PrEP at any point.
The study will be offered from two study sites: the first is a mobile clinic that rotates on a fixed schedule across the study area and the second is a fixed-location government primary healthcare clinic. The study will be open to confirmed HIV-negative individuals, including adolescent girls and young women (aged 15-29 years), young gender and sexually diverse populations aged 15-29 years (including men who have sex with men, transgender people, and non-binary people), and their collective sexual partners (including heterosexual, cisgender men) of any age.
The PrEPared to Choose (PtC) study seeks to describe patterns of persistence on HIV pre-exposure prophylaxis (PrEP) products, individually and overall, amongst a cohort of South African adolescents and youth when offered a choice between PrEP products in real-world public health facility and mobile clinic settings. The study will further seek to understand implementation barriers and enablers in PrEP adoption (decision to use any PrEP product), initiation (first dose of any PrEP product), and persistence amongst both PrEP users (adolescents and youth) and PrEP providers (healthcare providers).
This study will utilise a prospective cohort design that recruits 1800 adolescents and young people, specifically adolescent girls and young women, including pregnant and lacting women (15-29 years), young male key populations including men who have sex with men and male sex workers (15-29 years), and their collective intimate male partners (any age).
Participants will be invited to choose to initiate on one of three types of PrEP (injectable, oral, or vaginal ring PrEP). Participants will be able to use the same product throughout the study, switch between products, or stop and restart on PrEP at any point. Participants will be followed for 7 months to meet the primary outcome of short-term persistence and for a further 18 months to meet the secondary outcome of long-term persistence. Persistence will be defined as the continuous use of the selected product as intended with (a) \<7 day gap and (b) \<28 day gap in PrEP availability for daily dosing (oral PrEP), vaginal ring insertion, or subsequent injection. The 7-day window aligns with previous trial definitions of on-time dosing while the 28-day window aligns with pragmatic definitions of on-time dosing for PrEP in the South African context.
The three products available will include: (1) a Tenofovir-based oral tablet that needs to be taken daily and is provided as a 30-day supply of oral tablets; (2) a intra-vaginal silicone ring containing slow-release Dapivirine that provides HIV protection for up to 28 days; and (3) an intramuscular injection containing Cabotegravir that provides HIV protection for up to two months. The study will aim to recruit up to 900 participants that initiate on injectable PrEP, up to 600 participants that initiate on oral PrEP, and up to 300 participants that initiate on vaginal ring PrEP.
PrEP choice counselling will be co-created with PrEP providers and young PrEP users (members of an existing PrEP-orientated youth reference group) and delivered by trained, adolescent-friendly HIV counsellors. PrEP will be administered by NIMART trained (Nurse Initiated Management of Anti-Retroviral Therapy) nurses at two clinical sites: a stationary government primary health care facility and a mobile clinic service that rotates on a fixed schedule through the study area. Participants will initiate at a single site but remain eligible to receive subsequent product refills/doses at the other site if desired.
Participants will be recruited from the Klipfontein-Mitchells Plain Health sub-district (a peri-urban, high-density, low socio-economic setting) in Cape Town, South Africa. Participants can access the study through the mobile clinic (which rotates through the study area on a fixed schedule) or a local government primary healthcare facility. The target study population includes adolescent girls and young women (aged 15 -29 years) and their intimate male partners (>15 years). Gender and sexually diverse populations, including men who have sex with men, transgender women, and transgender men, are eligible for study enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants that select to use injectable PrEP (Cabotegravir long-acting) at baseline.
Drug: Cabotegravir long-acting
Participants that select to use oral PrEP at baseline.
Drug: Tenofovir emtricitabine
Participants that select to use vaginal ring PrEP (DapiRing) at baseline.
Drug: Dapivirine containing vaginal ring
3ml intramuscular injection containing 600mg of Cabotegravir
Also known as: Apretude
Oral tablet taken daily to PrEP HIV infection.
Intra-vaginal silicone ring containing slow-release Dapivirine, replaced every 28 days
Short-term persistence
Persistence (return for PrEP product within a scheduled visit window) over the short-term (7 months) will be measured and reported as persistent vs non-persistent continuation on each specific PrEP product (oral, injectable, ring) and on PrEP overall (accounting for continuation after switching to a different PrEP product). Non-persistence will be defined as failure to return for PrEP within (a) 7 days of the scheduled visit and (b) 28 days of the scheduled visit.
Time frame: 7 months
Primary implementation aim.
The combination of implementation strategies best achieve pre-exposure prophylaxis (PrEP) adoption, active implementation (initiation), and persistence (sustainment) outcomes over the short term (7 months) and the long term (18 months) will be collected and reported within a RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) framework. This will include implementation strategies that describe PrEP choice counselling, the integration of injectable PrEP into standard of care clinical practise, and the differentiating practises required for the effective delivery of PrEP from community based and healthcare facility based settings.
Time frame: 7 months; 18 months
Durable persistence
Persistence (return for PrEP product within a scheduled visit window) over the long-term (18 months) will be measured and reported as persistent vs non-persistent continuation on each specific PrEP product (oral, injectable, ring) and on PrEP overall (accounting for continuation after switching to a different PrEP product). Non-persistence will be defined as failure to return for PrEP within (a) 7 days of the scheduled visit and (b) 28 days of the scheduled visit.
Time frame: 18 months
Time on PrEP
Time on PrEP based on expected (e.g. injections given; product collections as logged in dispency records) vs actual (e.g. self-reported patterns of use by the oral and ring PrEP user) PrEP coverage.
Time frame: 18 months
Safety of PrEP products
Reported frequency, timing, and nature of self reported and/or clinically identified adverse events (including clinical events, intimate partner violence, and pregnancy and infant outcomes).
Time frame: 18 months
Tolerability of PrEP products
Descriptive reports of product tolerability as per the frequency, timing, and nature of self-reported adverse side effect records. Side effects are asked about by HIV counsellors and research nurses at each study visit and rention officers during retention communications.
Time frame: 18 months
Acceptability of PrEP products
Descriptive quantitative and qualitative summaries of reasons for pre-exposure prophylaxis (PrEP) pause or discontinuation. Qualitative questionnaires and in-depth interviews that include questions on PrEP product and PrEP service acceptability are held every 6 months with a sub-set of PrEP users.
Time frame: 18 months
HIV testing in a context of PrEP choice
Sensitivity and specificity of counsellor-administered 3rd and 4th generation rapid Antigen/Antibody (Ag/Ab) HIV test compared to laboratory-based NAAT (Nucleic Acid Amplification Tests) testing results in injectable pre-exposure prophylaxis-using (Cabotegrvair long-acting initiated) participants as measured at discreet timepoints (baseline, month 1, month 7, and month 18) throughout the study.
Time frame: 18 months
HIV incidence
HIV incidence (as determined by HIV rapid and laboratory NAAT tests at each study visit and an overview of the medical records of participants lost to follow up and its correlation with individual PrEP use patterns (including PrEP product choice, PrEP persistence, product switching, and/or PrEP pauses and discontinuation over the 18 month study period). This outcome will be reported, however, the sample size of the study is insufficient to allow for a formal analysis of HIV incidence.
Time frame: 18 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for Dec 2025, 22 months after the start.
Of 187 non-industry observational studies under HIV Infections, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 22 months is below that.
Counting every sponsor, half of 201 studies reached it within 38 months; a quarter within 16 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Desmond Tutu HIV Foundation